1. /
  2. About us /
  3. Our people and structure /
  4. Our people /
  5. Celine Deffrasnes
Our people

Dr Celine Deffrasnes

Senior Research Officer

Working groups

Celine.deffrasnes@burnet.edu.au
Dr Celine Deffrasnes

Background

Celine completed her PhD in microbiology and immunology at the Infectious Disease Research Centre and Laval University in Quebec City Canada and subsequently completed postdoctoral training In Viral Immunopathology (West Nile virus encephalitis) with Prof Nicholas King at the University of Sydney, in Disease Prevention & Detection (Hendra virus, paramyxoviruses, human & avian influenza viruses) with Dr Andrew Bean at the CSIRO/ACDP in Geelong and more recently in Viral Pathogenesis (Rabies virus & lyssaviruses) with Dr Greg Moseley at Monash University.

Celine brings a wealth of experience in molecular biology, virology, host-pathogen interactions, immune evasion, antivirals and the study of emerging viral pathogens and has a strong interest in research translation having completed The Bridge Program (MTP Connect).

Qualifications

  • 2002, BSc, Infectious Disease Research Centre and Laval Universite, Quebec, Canada
  • 2004, MSc, Infectious Disease Research Centre and Laval Universite, Quebec, Canada
  • 2009, PhD, Infectious Disease Research Centre and Laval Universite, Quebec, Canada

Burnet publications

15 Jan 2014

Therapeutic Inflammatory Monocyte Modulation Using Immune-Modifying Microparticles

Science Translational Medicine

Céline Deffrasnes

25 Oct 2013

Studying immunity to zoonotic diseases in the natural host — keeping it real

Nature reviews. Immunology

Céline Deffrasnes

01 Dec 2012

Inflammatory monocytes and the pathogenesis of viral encephalitis

Journal of Neuroinflammation

Céline Deffrasnes

Current projects

View 1 more
EVE-M®: enhancing the vaginal environment and microbiome

EVE-M®: enhancing the vaginal environment and microbiome

The vaginal microbiome is a key determinant of a women’s sexual and reproductive health. There is an unmet need for effective non-antibiotic-based strategies to target bacterial vaginosis and its adverse sequelae.

A novel gel for targeting vaginal inflammation to prevent HIV transmission

A novel gel for targeting vaginal inflammation to prevent HIV transmission

We have discovered that optimal vaginal Lactobacillus spp. make a product that has direct anti-inflammatory effects on cervicovaginal epithelial cells that could help prevent HIV.

EVE-M® (Enhancing the vaginal environment and microbiome)

EVE-M® (Enhancing the vaginal environment and microbiome)

The vaginal microbiome is a key determinant of a women’s sexual and reproductive health. In contrast to an optimal vaginal microbiome dominated by beneficial lactobacilli which is protective, a non-optimal vaginal microbiome promotes genital inflammation that increases the risk of sexually transmitted infections (STIs) including human immunodeficiency virus (HIV) and preterm birth. Bacterial vaginosis (BV) is the most common clinical manifestation of a non-optimal vaginal microbiome affecting 30% of reproductive age women globally. Current treatment options for BV rely on antibiotics which provide short-term resolution. BV reoccurs in ~60% of women within 6 months. There is an unmet need for effective non-antibiotic-based strategies to target BV and its adverse sequelae.

View 1 more
On this page